Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Code-based Diagnostic Algorithms for Idiopathic Pulmonary Fibrosis. Case Validation and Improvement.

Ley B, Urbania T, Husson G, Vittinghoff E, Brush DR, Eisner MD, Iribarren C, Collard HR.

Ann Am Thorac Soc. 2017 Jun;14(6):880-887. doi: 10.1513/AnnalsATS.201610-764OC.

2.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials.

Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H.

J Allergy Clin Immunol. 2017 May;139(5):1678-1680. doi: 10.1016/j.jaci.2016.12.953. Epub 2017 Jan 17. No abstract available.

3.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma.

Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ.

J Allergy Clin Immunol. 2017 May;139(5):1489-1495.e5. doi: 10.1016/j.jaci.2016.07.038. Epub 2016 Sep 14.

4.

Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort.

Putcha N, Barr RG, Han MK, Woodruff PG, Bleecker ER, Kanner RE, Martinez FJ, Smith BM, Tashkin DP, Bowler RP, Eisner MD, Rennard SI, Wise RA, Hansel NN; SPIROMICS Investigators.

Thorax. 2016;71:411-420. doi: 10.1136/thoraxjnl-2015-207487. Epub 2016 Mar 9.

5.

Adrenaline rush: an unusual presentation of phaeochromocytoma.

Lindsey B, Eisner MD, Mitchell HK, Clesham G.

BMJ Case Rep. 2015 Aug 30;2015. pii: bcr2015211472. doi: 10.1136/bcr-2015-211472.

6.

Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease.

Paulin LM, Diette GB, Blanc PD, Putcha N, Eisner MD, Kanner RE, Belli AJ, Christenson S, Tashkin DP, Han M, Barr RG, Hansel NN; SPIROMICS Research Group.

Am J Respir Crit Care Med. 2015 Mar 1;191(5):557-65. doi: 10.1164/rccm.201408-1407OC.

7.

Risk adjustment for health care financing in chronic disease: what are we missing by failing to account for disease severity?

Omachi TA, Gregorich SE, Eisner MD, Penaloza RA, Tolstykh IV, Yelin EH, Iribarren C, Dudley RA, Blanc PD.

Med Care. 2013 Aug;51(8):740-7. doi: 10.1097/MLR.0b013e318298082f.

8.

Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.

AAPS J. 2013 Apr;15(2):559-70. doi: 10.1208/s12248-013-9463-9. Epub 2013 Feb 15.

9.

Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts.

Iribarren C, Tolstykh IV, Miller MK, Sobel E, Eisner MD.

Am J Epidemiol. 2012 Dec 1;176(11):1014-24. doi: 10.1093/aje/kws181. Epub 2012 Nov 8.

PMID:
23139248
10.

Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.

Chen H, Eisner MD, Haselkorn T, Trzaskoma B.

Respir Med. 2013 Jan;107(1):60-7. doi: 10.1016/j.rmed.2012.09.008. Epub 2012 Oct 18.

11.

Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.

Eisner MD, Zazzali JL, Miller MK, Bradley MS, Schatz M.

J Asthma. 2012 Aug;49(6):642-8. doi: 10.3109/02770903.2012.690477.

PMID:
22793527
12.

Trends in the incidence of noncardiogenic acute respiratory failure: the role of race.

Cooke CR, Erickson SE, Eisner MD, Martin GS.

Crit Care Med. 2012 May;40(5):1532-8. doi: 10.1097/CCM.0b013e31824518f2.

13.

Omalizumab and the risk of malignancy: results from a pooled analysis.

Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J.

J Allergy Clin Immunol. 2012 Apr;129(4):983-9.e6. doi: 10.1016/j.jaci.2012.01.033. Epub 2012 Feb 23.

PMID:
22365654
14.

Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma.

Eisner MD, Yegin A, Trzaskoma B.

Chest. 2012 Jan;141(1):58-65. doi: 10.1378/chest.11-0020. Epub 2011 Sep 1.

PMID:
21885725
15.

Lebrikizumab treatment in adults with asthma.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG.

N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.

16.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.

Ann Intern Med. 2011 May 3;154(9):573-82. doi: 10.7326/0003-4819-154-9-201105030-00002.

PMID:
21536936
17.

Active and passive cigarette smoking and acute lung injury after severe blunt trauma.

Calfee CS, Matthay MA, Eisner MD, Benowitz N, Call M, Pittet JF, Cohen MJ.

Am J Respir Crit Care Med. 2011 Jun 15;183(12):1660-5. doi: 10.1164/rccm.201011-1802OC. Epub 2011 Mar 18.

18.

Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.

Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD.

Respir Res. 2011 Mar 23;12:35. doi: 10.1186/1465-9921-12-35.

19.

Comparison of urine cotinine and the tobacco-specific nitrosamine metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking.

Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, Sobczak A, Havel C, Jacob P, Benowitz NL.

Nicotine Tob Res. 2011 Mar;13(3):202-8. doi: 10.1093/ntr/ntq237. Epub 2011 Jan 21.

20.

Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury.

Calfee CS, Ware LB, Glidden DV, Eisner MD, Parsons PE, Thompson BT, Matthay MA; National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network.

Crit Care Med. 2011 Apr;39(4):711-7. doi: 10.1097/CCM.0b013e318207ec3c.

21.

Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function.

Singer J, Yelin EH, Katz PP, Sanchez G, Iribarren C, Eisner MD, Blanc PD.

J Cardiopulm Rehabil Prev. 2011 Mar-Apr;31(2):111-9. doi: 10.1097/HCR.0b013e3182033663.

22.

Development of disability in chronic obstructive pulmonary disease: beyond lung function.

Eisner MD, Iribarren C, Blanc PD, Yelin EH, Ackerson L, Byl N, Omachi TA, Sidney S, Katz PP.

Thorax. 2011 Feb;66(2):108-14. doi: 10.1136/thx.2010.137661. Epub 2010 Nov 3.

23.

Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients.

Hsieh SJ, Ware LB, Eisner MD, Yu L, Jacob P 3rd, Havel C, Goniewicz ML, Matthay MA, Benowitz NL, Calfee CS.

Crit Care Med. 2011 Jan;39(1):40-5. doi: 10.1097/CCM.0b013e3181fa4196.

24.

COPD and cognitive impairment: the role of hypoxemia and oxygen therapy.

Thakur N, Blanc PD, Julian LJ, Yelin EH, Katz PP, Sidney S, Iribarren C, Eisner MD.

Int J Chron Obstruct Pulmon Dis. 2010 Sep 7;5:263-9.

25.

Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers.

Benowitz N, Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, Sobczak A, Havel C, Jacob P 3rd.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2795-800. doi: 10.1158/1055-9965.EPI-10-0497. Epub 2010 Aug 30.

26.

An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease.

Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK, Balmes JR; Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):693-718. doi: 10.1164/rccm.200811-1757ST. Review.

PMID:
20802169
27.

An integrated model of environmental factors in adult asthma lung function and disease severity: a cross-sectional study.

Trupin L, Balmes JR, Chen H, Eisner MD, Hammond SK, Katz PP, Lurmann F, Quinlan PJ, Thorne PS, Yelin EH, Blanc PD.

Environ Health. 2010 May 20;9:24. doi: 10.1186/1476-069X-9-24.

28.

Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system.

Iribarren C, Tolstykh IV, Miller MK, Eisner MD.

Ann Allergy Asthma Immunol. 2010 May;104(5):371-7. doi: 10.1016/j.anai.2010.03.004.

PMID:
20486326
29.

The impact of a "low-intensity" versus "high-intensity" medical intensive care unit on patient outcomes in critically ill veterans.

Singer JP, Kohlwes J, Bent S, Zimmerman L, Eisner MD.

J Intensive Care Med. 2010 Jul;25(4):233-9. doi: 10.1177/0885066610366933.

30.

Effect of disaccharides on ion properties in milk-based systems.

Gao R, van Leeuwen HP, Temminghoff EJ, van Valenberg HJ, Eisner MD, van Boekel MA.

J Agric Food Chem. 2010 May 26;58(10):6449-57. doi: 10.1021/jf1002396.

PMID:
20426420
31.

Influence of anxiety on health outcomes in COPD.

Eisner MD, Blanc PD, Yelin EH, Katz PP, Sanchez G, Iribarren C, Omachi TA.

Thorax. 2010 Mar;65(3):229-34. doi: 10.1136/thx.2009.126201.

32.

Onset of depressive symptoms among adults with asthma: results from a longitudinal observational cohort.

Katz PP, Morris A, Julian L, Omachi T, Yelin EH, Eisner MD, Blanc PD.

Prim Care Respir J. 2010 Sep;19(3):223-30. doi: 10.4104/pcrj.2010.00012.

33.

An official American Thoracic Society workshop report: tobacco control initiatives within the American Thoracic Society.

Wewers ME, Bailey WC, Carlsen KH, Eisner MD, Folan P, Heath J, Klinnert MD, Kovesi T, Pien GW, Reichart VC, Talwar A, Thompson K; American Thoracic Society Subcommittee on Tobacco Control Initiatives.

Proc Am Thorac Soc. 2010 Feb;7(1):1-7. doi: 10.1513/pats.200811-120ST.

PMID:
20160142
34.

Measurement of COPD severity using a survey-based score: validation in a clinically and physiologically characterized cohort.

Eisner MD, Omachi TA, Katz PP, Yelin EH, Iribarren C, Blanc PD.

Chest. 2010 Apr;137(4):846-51. doi: 10.1378/chest.09-1855. Epub 2009 Dec 29.

35.

Secondhand smoke at work.

Eisner MD.

Curr Opin Allergy Clin Immunol. 2010 Apr;10(2):121-6. doi: 10.1097/ACI.0b013e32833649b3. Review.

PMID:
20035220
36.

Screening for depression in chronic obstructive pulmonary disease.

Julian LJ, Gregorich SE, Earnest G, Eisner MD, Chen H, Blanc PD, Yelin EH, Katz PP.

COPD. 2009 Dec;6(6):452-8. doi: 10.3109/15412550903341463.

37.

The impact of disability on depression among individuals with COPD.

Katz PP, Julian LJ, Omachi TA, Gregorich SE, Eisner MD, Yelin EH, Blanc PD.

Chest. 2010 Apr;137(4):838-45. doi: 10.1378/chest.09-1939. Epub 2009 Nov 20.

38.

Socioeconomic status, race and COPD health outcomes.

Eisner MD, Blanc PD, Omachi TA, Yelin EH, Sidney S, Katz PP, Ackerson LM, Sanchez G, Tolstykh I, Iribarren C.

J Epidemiol Community Health. 2011 Jan;65(1):26-34. doi: 10.1136/jech.2009.089722. Epub 2009 Oct 23.

39.

The COPD Helplessness Index: a new tool to measure factors affecting patient self-management.

Omachi TA, Katz PP, Yelin EH, Iribarren C, Knight SJ, Blanc PD, Eisner MD.

Chest. 2010 Apr;137(4):823-30. doi: 10.1378/chest.09-0764. Epub 2009 Oct 16.

40.

Clinical year in review III: Chronic obstructive pulmonary disease, treatment of tobacco dependence, lung cancer, and lung transplantation.

Eisner MD.

Proc Am Thorac Soc. 2009 Sep 15;6(6):500-5. doi: 10.1513/pats.200906-037TT. Review. No abstract available.

PMID:
19741257
41.

Clinical year in review II: Sepsis, mechanical ventilation, occupational and environmental lung disease, and sleep.

Ware LB, Eisner MD, Flaherty KR.

Proc Am Thorac Soc. 2009 Sep 15;6(6):494-9. doi: 10.1513/pats.200907-060TT. Review. No abstract available.

PMID:
19741256
42.

Depression and health-related quality of life in chronic obstructive pulmonary disease.

Omachi TA, Katz PP, Yelin EH, Gregorich SE, Iribarren C, Blanc PD, Eisner MD.

Am J Med. 2009 Aug;122(8):778.e9-15. doi: 10.1016/j.amjmed.2009.01.036.

43.

Longer term exposure to secondhand smoke and health outcomes in COPD: impact of urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.

Eisner MD, Jacob P 3rd, Benowitz NL, Balmes J, Blanc PD.

Nicotine Tob Res. 2009 Aug;11(8):945-53. doi: 10.1093/ntr/ntp091. Epub 2009 Jul 8.

44.

Obstructive sleep apnea: a risk factor for work disability.

Omachi TA, Claman DM, Blanc PD, Eisner MD.

Sleep. 2009 Jun;32(6):791-8.

45.

Further exploration of the links between occupational exposure and chronic obstructive pulmonary disease.

Blanc PD, Eisner MD, Earnest G, Trupin L, Balmes JR, Yelin EH, Gregorich SE, Katz PP.

J Occup Environ Med. 2009 Jul;51(7):804-10. doi: 10.1097/JOM.0b013e3181a7dd4e.

46.

The impact of SHS exposure on health status and exacerbations among patients with COPD.

Eisner MD, Iribarren C, Yelin EH, Sidney S, Katz PP, Sanchez G, Blanc PD.

Int J Chron Obstruct Pulmon Dis. 2009;4:169-76. Epub 2009 May 7.

47.

Secondhand smoke and obstructive lung disease: a causal effect?

Eisner MD.

Am J Respir Crit Care Med. 2009 Jun 1;179(11):973-4. doi: 10.1164/rccm.200903-0320ED. No abstract available.

PMID:
19458269
48.

A simple clinical predictive index for objective estimates of mortality in acute lung injury.

Cooke CR, Shah CV, Gallop R, Bellamy S, Ancukiewicz M, Eisner MD, Lanken PN, Localio AR, Christie JD; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network.

Crit Care Med. 2009 Jun;37(6):1913-20. doi: 10.1097/CCM.0b013e3181a009b4.

49.

The COPD severity score: a dynamic prediction tool for health-care utilization.

Omachi TA, Yelin EH, Katz PP, Blanc PD, Eisner MD.

COPD. 2008 Dec;5(6):339-46. doi: 10.1080/15412550802522700.

50.

Recent trends in acute lung injury mortality: 1996-2005.

Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD; NIH NHLBI ARDS Network.

Crit Care Med. 2009 May;37(5):1574-9. doi: 10.1097/CCM.0b013e31819fefdf.

Supplemental Content

Loading ...
Support Center